🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Joel B. Braunstein

C2N Diagnostics (United States)

ORCID: 0000-0002-1155-0206
MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease”.

Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

Alzheimer s & Dementia(2023)10.1002/alz.13542
N/A
3.4DataRank · unranked
149 citations

Oliver Langford, Rema Raman, Michael Donohue, Sara Abdel‐Latif, Matthew R. Meyer +16 more

Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial

Alzheimer s & Dementia(2024)10.1002/alz.13803
N/A
1.1DataRank · unranked
40 citations

Rema Raman, Andy Liu, Oliver Langford, Keith A. Johnson, Leona K. Shum +14 more

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Nature Reviews Neurology(2024)10.1038/s41582-024-00977-5
N/A
0.843DataRank · unranked
275 citations

Douglas Galasko, Ana C. Pereira, Gil D. Rabinovici, Stephen Salloway, Marc Suárez‐Calvet +30 more

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Alzheimer s & Dementia(2024)10.1002/alz.13764
N/A
0.717DataRank · unranked
118 citations

Kristopher M. Kirmess, Stephanie Eastwood, Traci L. Wente‐Roth, Faith Irvin, Mary S. Holubasch +20 more

Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia

Alzheimer s & Dementia(2025)10.1002/alz.14570
N/A
0DataRank · unranked
8 citations

Lianlian Du, Rachel Studer, Erin M. Jonaitis, Sanjay Asthana, Bradley T. Christian +11 more

Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals

Alzheimer s & Dementia(2025)10.1002/alz.70625
N/A
0DataRank · unranked
6 citations

Heather J. Wiste, Terry M. Therneau, Michael Griswold, Niklas Mattsson, Sebastian Palmqvist +20 more

Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET

Alzheimer s & Dementia(2025)10.1002/alz.14629
N/A
0DataRank · unranked
5 citations

Heather J. Wiste, Stephen D. Weigand, Terry M. Therneau, Michael Griswold, Joel B. Braunstein +13 more

Racial and ethnic differences in plasma p‐tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring(2025)10.1002/dad2.70164
N/A
0DataRank · unranked
3 citations

Rema Raman, Andy Liu, Oliver Langford, Joel B. Braunstein, Philip B. Verghese +10 more

Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment

npj Dementia(2025)10.1038/s44400-025-00026-y
N/A
0DataRank · unranked
1 citations

Tim West, Kris Kirmess, I. Fogelman, Sutapa Ray, Philip B. Verghese +4 more

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Molecular Neurodegeneration(2021)10.1186/s13024-021-00451-6
N/A
0DataRank · unranked
233 citations

Kristopher M. Kirmess, Matthew R. Meyer, Mary S. Holubasch, S Knapik, Yan Hu +10 more

Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study

Journal of Personalized Medicine(2025)10.3390/jpm15100469
N/A
0DataRank · unranked
0 citations

Robert M. Carlile, Kim G. Johnson, Darren R. Gitelman, Lawren VandeVrede, Demetrius M. Maraganore +7 more

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Clinica Chimica Acta(2021)10.1016/j.cca.2021.05.011
N/A
0DataRank · unranked
134 citations

Matthew R. Meyer, Mary S. Holubasch, S Knapik, Yan Hu, Erin N. Jackson +8 more

PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

Diagnostics(2024)10.3390/diagnostics14161739
N/A
0DataRank · unranked
14 citations

Matthew R. Meyer, Kristopher M. Kirmess, Traci L. Wente‐Roth, Faith Irvin, Mary S. Holubasch +6 more

Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study

Diagnostics(2025)10.3390/diagnostics15020167
N/A
0DataRank · unranked
9 citations

Demetrius M. Maraganore, Robert M. Carlile, Kim G. Johnson, David A. Merrill, Darren R. Gitelman +9 more